tetano
Editor, Senior Moderator
Transpl Infect Dis
. 2023 Nov 3:e14167.
doi: 10.1111/tid.14167. Online ahead of print. Post-acute sequelae of COVID-19 in solid organ transplant recipients
Rachel Sigler[SUP] 1 [/SUP], Karina Covarrubias[SUP] 2 [/SUP], Benjamin Chen[SUP] 3 [/SUP], Rodrigo Barriola Rubarth[SUP] 4 [/SUP], Kelly Torosian[SUP] 4 [/SUP], Claudia Ramirez Sanchez[SUP] 2 [/SUP], Ajay Bharti[SUP] 2 [/SUP], Victor DeGruttola[SUP] 5 [/SUP], Saima Aslam[SUP] 2 [/SUP]
Affiliations
Background: Post-acute sequelae of coronavirus disease 2019 (COVID-19) (PASC), defined as prolonged symptoms following an episode of COVID-19, is not well-characterized in solid organ transplant recipients (SOTR). In this study, we aimed to assess the prevalence of PASC in SOTR, its descriptive characteristics, and associated risk factors.
Methods: We retrospectively identified SOTRs with acute COVID-19 between June 1, 2020 and April 15, 2022, and abstracted demographic and medical history, characteristics of acute COVID-19 illness, and COVID-19 vaccination status. We defined PASC as ongoing/new symptoms present at 6 weeks or longer following acute COVID-19 diagnosis.
Results: Among 208 SOTRs with acute COVID-19, 72 (35%) developed PASC. Common symptoms were respiratory symptoms (67%), headache (40%), and difficulty concentrating (10%). Severe acute COVID-19 disease and presence of respiratory symptoms were associated with higher odds of PASC in multivariable analyses, while receipt of at least one COVID-19 vaccination prior to transplantation was protective.
Conclusion: We found that PASC occurs in about a third of SOTRs with acute COVID-19 and has similar symptoms as described previously in immunocompetent hosts. Pre-transplant vaccination may be protective. Further prospective multicenter studies are needed.
Keywords: COVID-19; immunocompromise; long COVID; post-acute sequelae of COVID-19; solid organ transplant.
. 2023 Nov 3:e14167.
doi: 10.1111/tid.14167. Online ahead of print. Post-acute sequelae of COVID-19 in solid organ transplant recipients
Rachel Sigler[SUP] 1 [/SUP], Karina Covarrubias[SUP] 2 [/SUP], Benjamin Chen[SUP] 3 [/SUP], Rodrigo Barriola Rubarth[SUP] 4 [/SUP], Kelly Torosian[SUP] 4 [/SUP], Claudia Ramirez Sanchez[SUP] 2 [/SUP], Ajay Bharti[SUP] 2 [/SUP], Victor DeGruttola[SUP] 5 [/SUP], Saima Aslam[SUP] 2 [/SUP]
Affiliations
- PMID: 37922371
- DOI: 10.1111/tid.14167
Background: Post-acute sequelae of coronavirus disease 2019 (COVID-19) (PASC), defined as prolonged symptoms following an episode of COVID-19, is not well-characterized in solid organ transplant recipients (SOTR). In this study, we aimed to assess the prevalence of PASC in SOTR, its descriptive characteristics, and associated risk factors.
Methods: We retrospectively identified SOTRs with acute COVID-19 between June 1, 2020 and April 15, 2022, and abstracted demographic and medical history, characteristics of acute COVID-19 illness, and COVID-19 vaccination status. We defined PASC as ongoing/new symptoms present at 6 weeks or longer following acute COVID-19 diagnosis.
Results: Among 208 SOTRs with acute COVID-19, 72 (35%) developed PASC. Common symptoms were respiratory symptoms (67%), headache (40%), and difficulty concentrating (10%). Severe acute COVID-19 disease and presence of respiratory symptoms were associated with higher odds of PASC in multivariable analyses, while receipt of at least one COVID-19 vaccination prior to transplantation was protective.
Conclusion: We found that PASC occurs in about a third of SOTRs with acute COVID-19 and has similar symptoms as described previously in immunocompetent hosts. Pre-transplant vaccination may be protective. Further prospective multicenter studies are needed.
Keywords: COVID-19; immunocompromise; long COVID; post-acute sequelae of COVID-19; solid organ transplant.